Isabel Fabregat
Madrid, MD 28029, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Corrigendum to: "The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1" [JHEP Reports 8 (2026) 101755].
Journal: JHEP reports : innovation in hepatology
Published: July 08, 2026
Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 17, 2025
Decoding tumor-stroma interactions: from molecular crosstalk to therapeutic targets.
Journal: FEBS open bio
Published: August 06, 2025
Regulatory Mechanisms of SPARC Overexpression in Melanoma Progression.
Journal: International journal of molecular sciences
Published: July 24, 2025
The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1.
Journal: JHEP reports : innovation in hepatology
Published: May 16, 2025
Inhibiting the TGF-β1 Pathway Reduces the Aggressiveness of Intrahepatic CCA HuCCT1 CD90-Positive Cells.
Journal: International journal of molecular sciences
Published: April 09, 2025
New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: March 25, 2025
New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics.
Journal: International journal of molecular sciences
Published: January 30, 2025
Moderate increase of MET in hepatocytes protects against cholestatic liver injury by promoting an effective antioxidant response.
Journal: The FEBS journal
Published: January 02, 2025
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.
Journal: NAR cancer
Published: October 17, 2024
ECM1: a novel matricellular protein with promising antifibrotic potential.
Journal: Gut
Published: September 07, 2024
NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts.
Journal: Signal transduction and targeted therapy
Published: September 02, 2024
Last Updated: 09/26/2026